rxstat › Classes › Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease (Gerd)
Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease (Gerd): shortage status in Canada
8 of the 12 drugs for peptic ulcer and gastroesophageal reflux disease (gerd) rxstat tracks are currently in shortage in Canada, including 1 designated Tier 3 (most serious) by Health Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.
Widespread shortageFamotidine3 of 13 reported products affected · est. return Sep 18, 2026Partial shortageCimetidine3 of 9 reported products affectedPartial shortageEsomeprazole12 of 26 reported products affected · est. return Oct 10, 2027Partial shortageLansoprazole6 of 22 reported products affected · est. return Dec 29, 2026Partial shortageOmeprazole10 of 22 reported products affected · est. return Aug 14, 2026Partial shortagePantoprazole7 of 35 reported products affected · est. return Sep 29, 2026Partial shortageRabeprazole4 of 21 reported products affected · est. return Jun 30, 2026Partial shortageRanitidine12 of 36 reported products affected · est. return Dec 30, 2022No current shortageClarithromycin Amoxicillin LansoprazoleNo current shortageDexlansoprazoleNo current shortageMisoprostolNo current shortageSucralfate
Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.